Tvardi Therapeutics Inc
Company Profile
Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USAT: +1 713 489-8654
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.70 | 71.20 | 0.81% |
| CAC 40 | 8,206.71 | 44.88 | 0.55% |
| DAX 40 | 24,188.63 | 6.68 | -0.03% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,330.91 | 76.10 | 0.74% |
| HKSE | 24,249.29 | 158.67 | -0.65% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 64,217.27 | 38.00 | 0.06% |
| NZX 50 Index | 13,202.16 | 51.49 | -0.39% |
| S&P 500 | 7,266.99 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,633.20 | 69.70 | 0.81% |
| SSE Composite Index | 3,987.01 | 6.21 | -0.16% |